PortalPublikationenCytogenetic risk score maintains its prognostic significance...

Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation

Standard

Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. / Nagler, Arnon; Labopin, Myriam; Canaani, Jonathan; Niittyvuopio, Riitta; Socié, Gerard; Kröger, Nicolaus; Itäla-Remes, Maija; Yakoub-Agha, Ibrahim; Labussière-Wallet, Hélène; Gallego-Hernanz, Maria P; Deconinck, Eric; Chevallier, Patrice; Finke, Jürgen; Esteve, Jordi; Mohty, Mohamad.

in: AM J HEMATOL, Jahrgang 95, Nr. 10, 10.2020, S. 1135-1141.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Nagler, A, Labopin, M, Canaani, J, Niittyvuopio, R, Socié, G, Kröger, N, Itäla-Remes, M, Yakoub-Agha, I, Labussière-Wallet, H, Gallego-Hernanz, MP, Deconinck, E, Chevallier, P, Finke, J, Esteve, J & Mohty, M 2020, 'Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation', AM J HEMATOL, Jg. 95, Nr. 10, S. 1135-1141. https://doi.org/10.1002/ajh.25905

APA

Nagler, A., Labopin, M., Canaani, J., Niittyvuopio, R., Socié, G., Kröger, N., Itäla-Remes, M., Yakoub-Agha, I., Labussière-Wallet, H., Gallego-Hernanz, M. P., Deconinck, E., Chevallier, P., Finke, J., Esteve, J., & Mohty, M. (2020). Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. AM J HEMATOL, 95(10), 1135-1141. https://doi.org/10.1002/ajh.25905

Vancouver

Nagler A, Labopin M, Canaani J, Niittyvuopio R, Socié G, Kröger N et al. Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. AM J HEMATOL. 2020 Okt;95(10):1135-1141. https://doi.org/10.1002/ajh.25905

Bibtex

@article{fbcd1642fd264f43a7e8f94ad7961b1e,
title = "Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation",
abstract = "While evidence for measurable residual disease (MRD) is a harbinger of inferior outcome in acute myeloid leukemia (AML) patients referred for allogeneic stem cell transplantation (allo-SCT), the exact clinical trajectory of specific patient subsets in this clinical setting is undefined. Using a recently published prognostic cytogenetic model (Canaani et al. Leukemia 2019) we evaluated whether this model applied also to studies of patients with positive MRD. The analysis comprised MRD+ patients in first complete remission undergoing allo-SCT from a matched sibling donor or unrelated donor. Seven hundred and seventy-five patients were evaluated with a median follow-up duration of 22 months. Cytogenetic risk score was favorable, intermediate/FLT3wt intermediate/FLT3-ITD3, and adverse in 15%, 28.3%, 37% and 19.7% of the patients, respectively. Favorable and intermediate/FLT3wt risk patients had 2-year leukemia-free survival rates of 78% and 61%, respectively, compared with only 50% and 37% for intermediate/FLT3-ITD3 and adverse risk patients, respectively (P < .001). In multivariate analysis adverse and intermediate/FLT3-ITD3 risk patients were more likely to experience disease relapse compared with favorable risk patients [hazard ratio (HR) = 3.9, 95% confidence interval (CI), 2.1-7.3; P < .001, and HR = 4.4, CI 95%, 2.4-7.8; P < .001, respectively]. The European society for blood and marrow transplantation cytogenetic risk score is a valuable adjunct for risk stratification of MRD+ AML patients.",
author = "Arnon Nagler and Myriam Labopin and Jonathan Canaani and Riitta Niittyvuopio and Gerard Soci{\'e} and Nicolaus Kr{\"o}ger and Maija It{\"a}la-Remes and Ibrahim Yakoub-Agha and H{\'e}l{\`e}ne Labussi{\`e}re-Wallet and Gallego-Hernanz, {Maria P} and Eric Deconinck and Patrice Chevallier and J{\"u}rgen Finke and Jordi Esteve and Mohamad Mohty",
note = "{\textcopyright} 2020 Wiley Periodicals LLC.",
year = "2020",
month = oct,
doi = "10.1002/ajh.25905",
language = "English",
volume = "95",
pages = "1135--1141",
journal = "AM J HEMATOL",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation

AU - Nagler, Arnon

AU - Labopin, Myriam

AU - Canaani, Jonathan

AU - Niittyvuopio, Riitta

AU - Socié, Gerard

AU - Kröger, Nicolaus

AU - Itäla-Remes, Maija

AU - Yakoub-Agha, Ibrahim

AU - Labussière-Wallet, Hélène

AU - Gallego-Hernanz, Maria P

AU - Deconinck, Eric

AU - Chevallier, Patrice

AU - Finke, Jürgen

AU - Esteve, Jordi

AU - Mohty, Mohamad

N1 - © 2020 Wiley Periodicals LLC.

PY - 2020/10

Y1 - 2020/10

N2 - While evidence for measurable residual disease (MRD) is a harbinger of inferior outcome in acute myeloid leukemia (AML) patients referred for allogeneic stem cell transplantation (allo-SCT), the exact clinical trajectory of specific patient subsets in this clinical setting is undefined. Using a recently published prognostic cytogenetic model (Canaani et al. Leukemia 2019) we evaluated whether this model applied also to studies of patients with positive MRD. The analysis comprised MRD+ patients in first complete remission undergoing allo-SCT from a matched sibling donor or unrelated donor. Seven hundred and seventy-five patients were evaluated with a median follow-up duration of 22 months. Cytogenetic risk score was favorable, intermediate/FLT3wt intermediate/FLT3-ITD3, and adverse in 15%, 28.3%, 37% and 19.7% of the patients, respectively. Favorable and intermediate/FLT3wt risk patients had 2-year leukemia-free survival rates of 78% and 61%, respectively, compared with only 50% and 37% for intermediate/FLT3-ITD3 and adverse risk patients, respectively (P < .001). In multivariate analysis adverse and intermediate/FLT3-ITD3 risk patients were more likely to experience disease relapse compared with favorable risk patients [hazard ratio (HR) = 3.9, 95% confidence interval (CI), 2.1-7.3; P < .001, and HR = 4.4, CI 95%, 2.4-7.8; P < .001, respectively]. The European society for blood and marrow transplantation cytogenetic risk score is a valuable adjunct for risk stratification of MRD+ AML patients.

AB - While evidence for measurable residual disease (MRD) is a harbinger of inferior outcome in acute myeloid leukemia (AML) patients referred for allogeneic stem cell transplantation (allo-SCT), the exact clinical trajectory of specific patient subsets in this clinical setting is undefined. Using a recently published prognostic cytogenetic model (Canaani et al. Leukemia 2019) we evaluated whether this model applied also to studies of patients with positive MRD. The analysis comprised MRD+ patients in first complete remission undergoing allo-SCT from a matched sibling donor or unrelated donor. Seven hundred and seventy-five patients were evaluated with a median follow-up duration of 22 months. Cytogenetic risk score was favorable, intermediate/FLT3wt intermediate/FLT3-ITD3, and adverse in 15%, 28.3%, 37% and 19.7% of the patients, respectively. Favorable and intermediate/FLT3wt risk patients had 2-year leukemia-free survival rates of 78% and 61%, respectively, compared with only 50% and 37% for intermediate/FLT3-ITD3 and adverse risk patients, respectively (P < .001). In multivariate analysis adverse and intermediate/FLT3-ITD3 risk patients were more likely to experience disease relapse compared with favorable risk patients [hazard ratio (HR) = 3.9, 95% confidence interval (CI), 2.1-7.3; P < .001, and HR = 4.4, CI 95%, 2.4-7.8; P < .001, respectively]. The European society for blood and marrow transplantation cytogenetic risk score is a valuable adjunct for risk stratification of MRD+ AML patients.

U2 - 10.1002/ajh.25905

DO - 10.1002/ajh.25905

M3 - SCORING: Journal article

C2 - 32530520

VL - 95

SP - 1135

EP - 1141

JO - AM J HEMATOL

JF - AM J HEMATOL

SN - 0361-8609

IS - 10

ER -